Article
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Dec 2023
Goetz M P, Bagegni N A, Batist G, Brufsky A, Cristofanilli M A, Damodaran S, Daniel B R, Fleming G F, Gradishar W J, Graff S L, Grosse Perdekamp M T, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, Pluard T J, Rugo H S, Sammons S L, Schwartzberg L S, Stover D G, Vidal G A, Wang G, Warner E, Yerushalmi R, Plourde P V, Portman D J, Gal-Yam E N
Abstract excerpt
BACKGROUND: Acquired estrogen receptor alpha (ER/ESR1) mutations commonly cause endocrine resistance in ER+ metastatic breast cancer (mBC). Lasofoxifene, a novel selective ER modulator, stabilizes an antagonist conformation of wild-type and ESR1-mutated ER-ligand binding domains, and has antitumor activity in ESR1-mutated xenografts. PATIENTS AND METHODS: In this open-label, randomized, phase II, multicenter,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.